ACE and COVID-19: People with hypertension or cardiovascular disease have a higher risk of COVID-19 infection and severe COVID-19 course potentially be associated with the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for treatments.